Amgen colorectal cancer drug gains expanded U.S. approval

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN) says the FDA has approved its Vectibix drug as an initial treatment in patients with a type of advanced colorectal cancer who first undergo genetic screening.

AMGN says the drug was cleared as an initial treatment in conjunction with chemotherapy for patients whose tumors have a gene mutation that renders their cancer susceptible to the medicine.

The FDA agency also cleared Qiagen’s (QGEN) test that can show whether Vectibix will be effective in patients.